pharmaand GmbH Gains FDA Regular Approval for Rucaparib in BRCAm Metastatic Prostate Cancer

The accelerated-to-regular approval conversion of rucaparib (Rubraca) by pharmaand GmbH on December 17, 2025, closes a confirmatory trial obligation that regulatory teams have tracked since the 2020 accelerated approval, and resets the compliance baseline for companion diagnostic alignment across the mCRPC treatment pathway.

The regular approval covers adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patient selection requires an FDA-approved companion diagnostic (CDx), a requirement that places CDx manufacturers and their quality systems directly in scope of any commercial launch readiness review.

Efficacy was confirmed through TRITON3 (NCT02975934), the randomized, open-label trial mandated as a condition of the 2020 accelerated approval. Among the 302 BRCAm patients, median radiographic progression-free survival (rPFS) was 11.2 months for rucaparib versus 6.4 months for physician's choice (HR 0.50; 95% CI: 0.36, 0.69; p<0.0001). Overall survival difference was not statistically significant (23.2 vs. 21.2 months; HR 0.91). An exploratory analysis of the 103 ATMm patients showed rPFS HR of 0.95 and OS HR of 1.21, confirming that the population-level benefit is attributable to BRCAm patients, a finding with direct implications for CDx-driven patient selection protocols.

For QA and regulatory leads, the CDx obligation is the sharper operational read. Any site dispensing Rubraca must verify that patient selection is conducted using an FDA-approved diagnostic, meaning CDx manufacturers supplying those assays carry a parallel GMP and analytical validation burden under 21 CFR Part 820 and applicable ICH Q10 quality system expectations. Gaps in CDx supply continuity or assay performance documentation could interrupt patient access and attract regulatory scrutiny.

The prescribing information carries warnings for myelodysplastic syndrome/acute myeloid leukemia and embryo-fetal toxicity. The recommended dose is 600 mg twice daily (two 300 mg tablets; total daily dose 1,200 mg), taken orally with or without food until disease progression or unacceptable toxicity. The FDA completed this review one month ahead of the goal date, with the applicant's voluntary Assessment Aid submission cited as a contributing factor.

With the confirmatory trial obligation now discharged and regular approval in place, the near-term checkpoint for manufacturing and regulatory teams is ensuring CDx quality documentation and patient selection procedures are audit-ready ahead of any post-approval inspection cycle.

Source: FDA Oncology Center of Excellence via FDA.gov Drugs RSS Feed, May 6, 2026.